A very-low-calorie ketogenic diet normalises obesity-related enhanced levels of erythropoietin compared with a low-calorie diet or bariatric surgery
Loading...
Identifiers
Publication date
Advisors
Tutors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
Purpose
Nutritional ketosis synergistically with body-weight loss induced by a very-low-calorie ketogenic diet (VLCKD) has proven to be effective in improving obesity-related pathophysiology. Recently, growing attention has been focused on the relation between erythropoietin (EPO) and obesity. Thus, this study aims to investigate whether nutritional ketosis and weight loss induced by a VLCKD modify the circulating levels of EPO in patients with obesity in comparison with the effect of low-calorie diet (LCD) or bariatric surgery (BS).
Methods
EPO levels, iron status and body composition parameters were evaluated in 72 patients with overweight or obesity and 27 normal-weight subjects at baseline and after the three different weight-reduction therapies (VLCKD, LCD and BS) in 69 patients with excess body weight. β-hydroxybutyrate levels were also measured in the VLCKD group. The follow-up was established at 2–3 months and 4–6 months.
Results
It was found that EPO levels were higher in morbid obesity and correlated with higher basal weight, fat mass (FM) and fat-free mass (FFM) in the overall sample. High baseline EPO levels were also correlated with higher impact on the course of weight loss and changes in FM and FFM induced by the three weight-loss interventions. Furthermore, the VLCKD induced a decrease in EPO levels coinciding with maximum ketosis, which was maintained over time, while statistically significant changes were not observed after LCD and BS.
Conclusion
The obesity-related increased EPO levels are restored after VLCKD intervention at the time of maximum ketosis, suggesting a potential role of the nutritional ketosis induced by the VLCKD. Baseline EPO levels could be a biomarker of response to a weight-loss therapy
Description
Bibliographic citation
J Endocrinol Invest (2024)
Relation
Has part
Has version
Is based on
Is part of
Is referenced by
Is version of
Requires
Publisher version
https://doi.org/10.1007/s40618-024-02364-9Sponsors
This work was supported by PronoKal Group® and grants from the Instituto de Salud Carlos III (ISCIII)-Subdireccion General de Evaluacion y Fomento de la Investigacion; European Regional Development Fund (ERDF) (PI20/00650, PI20/00628 and CP17/00088 research projects and CIBERobn) and by Xunta de Galicia-GAIN (IN607B2020/09). Ana B Crujeiras is funded by a Miguel Servet research contract (CP17/00088 and CPII22/00008) and Antia Fernandez-Pombo was funded by a Rio Hortega research contract (CM20/00155) from the ISCIII, co-financed by ERDF, received funding from the Fundación Alfonso Martín Escudero and is currently funded by a Juan Rodes research contract (JR23/00042) from the ISCIII, co-financed by ERDF. Paula M Lorenzo was funded by a predoctoral grant from Xunta de Galicia (IN606-2020/013)
Rights
Atribución 4.0 Internacional
© The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License
© The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License



